Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression

Sponsor
First Affiliated Hospital of Zhejiang University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06044324
Collaborator
(none)
42
1
2
31
1.4

Study Details

Study Description

Brief Summary

Major depressive disorder (MDD) exhibit reduced visual motor perception, which affects prognosis. Metabolic substance changes and abnormal neural activity in the middle temporal visual area (MT) mediate this perceptual dysfunction. The main questions are: •there is no conclusive evidence of impairment of visual motion suppression in treatment-resistant depression (TRD); •it is unknown that functional abnormalities in the MT of TRD patients mediate possible changes in visual perception •lack of treatment for deficit in visual motor perception; •mechanisms behind the intervention process need to be explored. The goal of this clinical trial is to understand the function of visual motor perception in TRD, to validate the effect of the MT on visual motion perception and to explore the effectiveness of the intervention as well as the neurophysiological mechanisms.

This study was planned to •explore any differences in visual motor perception and function of MT between TRD and healthy controls; •analyze the influence of neurobiological changes in MT and related brain regions on visual motion perception; •investigate the effects of rTMS intervention in MT for treatment of impaired visual perception function in TRD; •studying potential therapeutic mechanisms by PET/MRI imaging.

Participants will divide into TRD group and HC group. Clinical symptoms, scales, visual perception suppression index, PET/MRI, electrophysiology and other clinical data were collected at baseline for both two groups. TRD group received high-frequency rTMS stimulation targeting the MT. Besides, psychological scales, visual suppression index, PET/MRI, electrophysiology and other clinical data were collected during the intervention and after treatment.

The researchers will •compare the differences in visual perceptual function and neurobiological characteristics between the TRD group and the HC group in baseline; •analyze the impact of MT and related brain regions in visual motion perception; •compare the suppression index before and after intervention in TRD to discuss the feasibility of rTMS stimulation targeting the MT to improve visual motion perception abnormalities;•utilize the changes in clinical data of PET/MRI and electrophysiology before and after the treatment of TRD group to explore the possible underlying mechanisms during the treatment process.

Condition or Disease Intervention/Treatment Phase
  • Device: Repetitive Transcranial Magnetic Stimulation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
42 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Prospective Study on the Effectiveness of 18F-UCB-H Positron Emission Tomography Imaging in the Diagnosis of Repetitive Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
May 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Repetitive Transcranial Magnetic Stimulation

Stimulation site: According to the localization of neural orientation navigation system, magnetic resonance data was read in Brainsight software, and three-dimensional brain reconstruction was carried out. The stimulation target was located in the coordinates of Montreal Neurological Institute (MNI), which was located in the left middle temporal (-43, -73, 10). Treatment intensity was 100% exercise threshold, continuous 10Hz stimulation, repeated 75 times, that is, 3000 pulses per treatment, 2 times a day, stimulation lasted for 4 seconds with a 26-second interval for 37.5 minutes, continuous stimulation for 5 days, 2 days rest interval, and 5 days of continuous stimulation.

Device: Repetitive Transcranial Magnetic Stimulation
Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT. Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.

No Intervention: HC observation

Collect data on healthy controls without stimulation. The subjects get clinical evaluation, blood sample collection, positron emission tomography-magnetic resonance scanning, and electrophysiological monitoring.

Outcome Measures

Primary Outcome Measures

  1. Change in Suppression Index after treatment [Baseline]

    Suppression Index (SI) defined as the difference of log10 thresholds for large versus small stimuli of gratings, is able to quantify the suppression strength. The higher the numerical value, the more severe the visual motor perception deficit.

  2. Change in Suppression Index after treatment [2 weeks]

    Suppression Index (SI) defined as the difference of log10 thresholds for large versus small stimuli of gratings, is able to quantify the suppression strength. The higher the numerical value, the more severe the visual motor perception deficit.

  3. Hamilton Depression Scale (24-items) Total Score Change [Baseline]

    The Hamilton Depression Scale (24-items), is a 24 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. It's considered the gold standard for rating depression severity and used frequently in clinical trials. Higher HAM-D24 score indicates more severe depression, and each item yields a score of 0 to 4. The higher scores representing more severe levels of depression. Remission is defined as HAM-D24 ≤8. A reduction of 50% or more in total score from Baseline indicates clinical response.

  4. Hamilton Depression Scale (24-items) Total Score Change [2 weeks]

    The Hamilton Depression Scale (24-items), is a 24 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. It's considered the gold standard for rating depression severity and used frequently in clinical trials. Higher HAM-D24 score indicates more severe depression, and each item yields a score of 0 to 4. The higher scores representing more severe levels of depression. Remission is defined as HAM-D24 ≤8. A reduction of 50% or more in total score from Baseline indicates clinical response.

  5. Change in synaptic density using positron emission tomography/magnetic resonance imaging [Baseline]

    Positron emission tomography/magnetic resonance imaging (PET/MRI) is a fusion of PET and MRI, which integrates pathophysiological changes with morphological structure. Research using PET/MRI in major depression has shown that there are alterations in the snyaptic density of certain brain regions in people with the condition and synaptic dysfunction in the dorsolateral prefrontal cortex may have implications for the downstream organization of functional networks. The SV2A radioligand [11C]UCB-H can examine snyaptic density in human brain. And brain structure, function connectivity and spectrum of metabolic substances can be measured by MRI. Overall, PET/MRI has advantages for the diagnosis of major depression and the evaluation of treatment effects.

  6. Change in synaptic density using positron emission tomography/magnetic resonance imaging [2 weeks]

    Positron emission tomography/magnetic resonance imaging (PET/MRI) is a fusion of PET and MRI, which integrates pathophysiological changes with morphological structure. Research using PET/MRI in major depression has shown that there are alterations in the snyaptic density of certain brain regions in people with the condition and synaptic dysfunction in the dorsolateral prefrontal cortex may have implications for the downstream organization of functional networks. The SV2A radioligand [11C]UCB-H can examine snyaptic density in human brain. And brain structure, function connectivity and spectrum of metabolic substances can be measured by MRI. Overall, PET/MRI has advantages for the diagnosis of major depression and the evaluation of treatment effects.

Secondary Outcome Measures

  1. Change in Suppression Index after treatment [1 week]

    Suppression Index (SI) defined as the difference of log10 thresholds for large versus small stimuli of gratings, is able to quantify the suppression strength. The higher the numerical value, the more severe the visual motor perception deficit.

  2. Change in Suppression Index after treatment [6 weeks]

    Suppression Index (SI) defined as the difference of log10 thresholds for large versus small stimuli of gratings, is able to quantify the suppression strength. The higher the numerical value, the more severe the visual motor perception deficit.

  3. Change in the score of Visual Analog Scale (VAS) [Baseline]

    Subjective experience of time was measured by the VAS, which consists of a 100-mm vertical line representing the experience of time from slowest (i.e., -50 mm) to fastest (i.e., +50 mm). In this nonverbal dimensional task, subjects were asked to label how fast or slow they experienced the flow of time on the day of the survey.

  4. Change in the score of Visual Analog Scale (VAS) [1 week]

    Subjective experience of time was measured by the VAS, which consists of a 100-mm vertical line representing the experience of time from slowest (i.e., -50 mm) to fastest (i.e., +50 mm). In this nonverbal dimensional task, subjects were asked to label how fast or slow they experienced the flow of time on the day of the survey.

  5. Change in the score of Visual Analog Scale (VAS) [2 weeks]

    Subjective experience of time was measured by the VAS, which consists of a 100-mm vertical line representing the experience of time from slowest (i.e., -50 mm) to fastest (i.e., +50 mm). In this nonverbal dimensional task, subjects were asked to label how fast or slow they experienced the flow of time on the day of the survey.

  6. Change in the score of Visual Analog Scale (VAS) [6 weeks]

    Subjective experience of time was measured by the VAS, which consists of a 100-mm vertical line representing the experience of time from slowest (i.e., -50 mm) to fastest (i.e., +50 mm). In this nonverbal dimensional task, subjects were asked to label how fast or slow they experienced the flow of time on the day of the survey.

  7. Change in the score of Motor Agitation and Retardation Scale [Baseline]

    The Motor Agitation and Retardation Scale (MARS) is designed to assess psychomotor deficits in depressed patients and consists of five major body categories including eyes, face, voice, limbs, and trunk. The severity of each item ranges from 1 to 4, with 4 being the most severe. It takes an estimated 10 to 15 minutes to complete the assessment. The descriptions and explanations of the items are intended to be simple and practical.

  8. Change in the score of Motor Agitation and Retardation Scale [1 week]

    The Motor Agitation and Retardation Scale (MARS) is designed to assess psychomotor deficits in depressed patients and consists of five major body categories including eyes, face, voice, limbs, and trunk. The severity of each item ranges from 1 to 4, with 4 being the most severe. It takes an estimated 10 to 15 minutes to complete the assessment. The descriptions and explanations of the items are intended to be simple and practical.

  9. Change in the score of Motor Agitation and Retardation Scale [2 weeks]

    The Motor Agitation and Retardation Scale (MARS) is designed to assess psychomotor deficits in depressed patients and consists of five major body categories including eyes, face, voice, limbs, and trunk. The severity of each item ranges from 1 to 4, with 4 being the most severe. It takes an estimated 10 to 15 minutes to complete the assessment. The descriptions and explanations of the items are intended to be simple and practical.

  10. Change in the score of Motor Agitation and Retardation Scale [6 weeks]

    The Motor Agitation and Retardation Scale (MARS) is designed to assess psychomotor deficits in depressed patients and consists of five major body categories including eyes, face, voice, limbs, and trunk. The severity of each item ranges from 1 to 4, with 4 being the most severe. It takes an estimated 10 to 15 minutes to complete the assessment. The descriptions and explanations of the items are intended to be simple and practical.

  11. Hamilton Depression Scale (24-items) Total Score Change [1 weeks]

    The Hamilton Depression Scale (24-items), is a 24 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. It's considered the gold standard for rating depression severity and used frequently in clinical trials. Higher HAM-D24 score indicates more severe depression, and each item yields a score of 0 to 4. The higher scores representing more severe levels of depression. Remission is defined as HAM-D24 ≤8. A reduction of 50% or more in total score from Baseline indicates clinical response.

  12. Hamilton Depression Scale (24-items) Total Score Change [6 weeks]

    The Hamilton Depression Scale (24-items), is a 24 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. It's considered the gold standard for rating depression severity and used frequently in clinical trials. Higher HAM-D24 score indicates more severe depression, and each item yields a score of 0 to 4. The higher scores representing more severe levels of depression. Remission is defined as HAM-D24 ≤8. A reduction of 50% or more in total score from Baseline indicates clinical response.

  13. Change in the rate of Hamilton Anxiety Scale score [Baseline]

    Hamilton Anxiety Scale is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients. Each item on the scale is rated on a 5-point scale from 0 (not present) to 4 (severe), with the total score ranging from 0 to 68. Higher scores indicate higher levels of anxiety. The HAMA-17 is often used in clinical and research settings to assess the severity of anxiety symptoms and to evaluate the effectiveness of treatments for anxiety. It is a more comprehensive version of the HAMA that includes additional items to capture a broader range of anxiety symptoms.

  14. Change in the rate of Hamilton Anxiety Scale score [1 week]

    Hamilton Anxiety Scale is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients. Each item on the scale is rated on a 5-point scale from 0 (not present) to 4 (severe), with the total score ranging from 0 to 68. Higher scores indicate higher levels of anxiety. The HAMA-17 is often used in clinical and research settings to assess the severity of anxiety symptoms and to evaluate the effectiveness of treatments for anxiety. It is a more comprehensive version of the HAMA that includes additional items to capture a broader range of anxiety symptoms.

  15. Change in the rate of Hamilton Anxiety Scale score [2 weeks]

    Hamilton Anxiety Scale is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients. Each item on the scale is rated on a 5-point scale from 0 (not present) to 4 (severe), with the total score ranging from 0 to 68. Higher scores indicate higher levels of anxiety. The HAMA-17 is often used in clinical and research settings to assess the severity of anxiety symptoms and to evaluate the effectiveness of treatments for anxiety. It is a more comprehensive version of the HAMA that includes additional items to capture a broader range of anxiety symptoms.

  16. Change in the rate of Hamilton Anxiety Scale score [6 weeks]

    Hamilton Anxiety Scale is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients. Each item on the scale is rated on a 5-point scale from 0 (not present) to 4 (severe), with the total score ranging from 0 to 68. Higher scores indicate higher levels of anxiety. The HAMA-17 is often used in clinical and research settings to assess the severity of anxiety symptoms and to evaluate the effectiveness of treatments for anxiety. It is a more comprehensive version of the HAMA that includes additional items to capture a broader range of anxiety symptoms.

  17. the Chinese version of the Snaith-Hamilton Pleasure Scale [Baseline]

    The Chinese version of the Snaith-Hamilton Pleasure Scale is a tool to assess pleasure deficit in depressed patients. A total of 14 items, each with a score of 1 to 4, will be used to calculate the total score from 14 to 56. The higher the score, the more severe the pleasure deficit.

  18. the Chinese version of the Snaith-Hamilton Pleasure Scale [1 week]

    The Chinese version of the Snaith-Hamilton Pleasure Scale is a tool to assess pleasure deficit in depressed patients. A total of 14 items, each with a score of 1 to 4, will be used to calculate the total score from 14 to 56. The higher the score, the more severe the pleasure deficit.

  19. the Chinese version of the Snaith-Hamilton Pleasure Scale [2 weeks]

    The Chinese version of the Snaith-Hamilton Pleasure Scale is a tool to assess pleasure deficit in depressed patients. A total of 14 items, each with a score of 1 to 4, will be used to calculate the total score from 14 to 56. The higher the score, the more severe the pleasure deficit.

  20. the Chinese version of the Snaith-Hamilton Pleasure Scale [6 weeks]

    The Chinese version of the Snaith-Hamilton Pleasure Scale is a tool to assess pleasure deficit in depressed patients. A total of 14 items, each with a score of 1 to 4, will be used to calculate the total score from 14 to 56. The higher the score, the more severe the pleasure deficit.

  21. Change in the rate of Beck Scale of Suicidal Ideation score [Baseline]

    Beck Scale of Suicidal Ideation is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week. The BSI score ranges from 0 to 63, with higher scores indicating worse outcomes and lower scores indicating better outcomes.

  22. Change in the rate of Beck Scale of Suicidal Ideation score [1 week]

    Beck Scale of Suicidal Ideation is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week. The BSI score ranges from 0 to 63, with higher scores indicating worse outcomes and lower scores indicating better outcomes.

  23. Change in the rate of Beck Scale of Suicidal Ideation score [2 weeks]

    Beck Scale of Suicidal Ideation is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week. The BSI score ranges from 0 to 63, with higher scores indicating worse outcomes and lower scores indicating better outcomes.

  24. Change in the rate of Beck Scale of Suicidal Ideation score [6 weeks]

    Beck Scale of Suicidal Ideation is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week. The BSI score ranges from 0 to 63, with higher scores indicating worse outcomes and lower scores indicating better outcomes.

  25. Change in the Laukes Emotional Intensity Scale score [Baseline]

    The Laukes Emotional Intensity Scale (LEIS) was one of the first instruments successfully used to assess emotional retardation due to SSRI. The scale is a self-report scale designed to evaluate a subject's emotional intensity rather than frequency. The assessment consists of 18 questions on a 5-point scale assessing the subject's emotional state compared to "usual". The total score ranges from -36 to 36, representing very low to very high emotional intensity.

  26. Change in the Laukes Emotional Intensity Scale score [1 week]

    The Laukes Emotional Intensity Scale (LEIS) was one of the first instruments successfully used to assess emotional retardation due to SSRI. The scale is a self-report scale designed to evaluate a subject's emotional intensity rather than frequency. The assessment consists of 18 questions on a 5-point scale assessing the subject's emotional state compared to "usual". The total score ranges from -36 to 36, representing very low to very high emotional intensity.

  27. Change in the Laukes Emotional Intensity Scale score [2 weeks]

    The Laukes Emotional Intensity Scale (LEIS) was one of the first instruments successfully used to assess emotional retardation due to SSRI. The scale is a self-report scale designed to evaluate a subject's emotional intensity rather than frequency. The assessment consists of 18 questions on a 5-point scale assessing the subject's emotional state compared to "usual". The total score ranges from -36 to 36, representing very low to very high emotional intensity.

  28. Change in the Laukes Emotional Intensity Scale score [6 weeks]

    The Laukes Emotional Intensity Scale (LEIS) was one of the first instruments successfully used to assess emotional retardation due to SSRI. The scale is a self-report scale designed to evaluate a subject's emotional intensity rather than frequency. The assessment consists of 18 questions on a 5-point scale assessing the subject's emotional state compared to "usual". The total score ranges from -36 to 36, representing very low to very high emotional intensity.

  29. Change in the Clinically Useful Depression Outcome Scale-Mixed Subscale score [Baseline]

    The Useful Depression Outcome Scale-Mixed Subscale (CUDOS-M) is a revised scale based on the CUDOS with items added and subtracted, combining the criteria for evaluating typical manic/hypomanic episodes and depressive episodes; it is a self-assessment scale used for prognostic assessment of patients with depressive disorders with 13 rating items. Total score from 0 to 52, the higher the score the more serious the situation is.

  30. Change in the score of THINC-it [Baseline]

    THINC-it is a computerized cognitive screening tool that is designed to assess cognitive function in adults. THINC-it stands for "THINking Clearly," and it consist of 1 subjective (5-item Cognitive Impairment in Depression Questionnaire) and 4 objective (Choice Reaction Time, 1-Back Memory Task, Digit Symbol Replacement Test, and the Connectivity Test). The tool is administered on a tablet or computer, and it takes approximately 20 minutes to complete.

  31. Change in the score of THINC-it [1 week]

    THINC-it is a computerized cognitive screening tool that is designed to assess cognitive function in adults. THINC-it stands for "THINking Clearly," and it consist of 1 subjective (5-item Cognitive Impairment in Depression Questionnaire) and 4 objective (Choice Reaction Time, 1-Back Memory Task, Digit Symbol Replacement Test, and the Connectivity Test). The tool is administered on a tablet or computer, and it takes approximately 20 minutes to complete.

  32. Change in the score of THINC-it [2 weeks]

    THINC-it is a computerized cognitive screening tool that is designed to assess cognitive function in adults. THINC-it stands for "THINking Clearly," and it consist of 1 subjective (5-item Cognitive Impairment in Depression Questionnaire) and 4 objective (Choice Reaction Time, 1-Back Memory Task, Digit Symbol Replacement Test, and the Connectivity Test). The tool is administered on a tablet or computer, and it takes approximately 20 minutes to complete.

  33. Change in the score of THINC-it [6 weeks]

    THINC-it is a computerized cognitive screening tool that is designed to assess cognitive function in adults. THINC-it stands for "THINking Clearly," and it consist of 1 subjective (5-item Cognitive Impairment in Depression Questionnaire) and 4 objective (Choice Reaction Time, 1-Back Memory Task, Digit Symbol Replacement Test, and the Connectivity Test). The tool is administered on a tablet or computer, and it takes approximately 20 minutes to complete.

  34. Change in electroencephalogram [Baseline]

    Electroencephalogram is collected from 64 electrodes. EEG can be used to identify patterns of brain activity that are associated with the condition and to inform treatment decisions. EEG can be a useful tool for identifying patterns of brain activity that are associated with TRD and for guiding treatment decisions. Neurofeedback and TMS are two approaches that have shown promise in the treatment of TRD. several parameters are analyzed to identify patterns of brain activity that may be associated with the condition. These parameters include: Alpha power, Beta power, Theta power, Delta power, Coherence, and more.

  35. Change in electroencephalogram [1 week]

    Electroencephalogram is collected from 64 electrodes. EEG can be used to identify patterns of brain activity that are associated with the condition and to inform treatment decisions. EEG can be a useful tool for identifying patterns of brain activity that are associated with TRD and for guiding treatment decisions. Neurofeedback and TMS are two approaches that have shown promise in the treatment of TRD. several parameters are analyzed to identify patterns of brain activity that may be associated with the condition. These parameters include: Alpha power, Beta power, Theta power, Delta power, Coherence, and more.

  36. Change in electroencephalogram [2 weeks]

    Electroencephalogram is collected from 64 electrodes. EEG can be used to identify patterns of brain activity that are associated with the condition and to inform treatment decisions. EEG can be a useful tool for identifying patterns of brain activity that are associated with TRD and for guiding treatment decisions. Neurofeedback and TMS are two approaches that have shown promise in the treatment of TRD. several parameters are analyzed to identify patterns of brain activity that may be associated with the condition. These parameters include: Alpha power, Beta power, Theta power, Delta power, Coherence, and more.

  37. Change in electroencephalogram [6 weeks]

    Electroencephalogram is collected from 64 electrodes. EEG can be used to identify patterns of brain activity that are associated with the condition and to inform treatment decisions. EEG can be a useful tool for identifying patterns of brain activity that are associated with TRD and for guiding treatment decisions. Neurofeedback and TMS are two approaches that have shown promise in the treatment of TRD. several parameters are analyzed to identify patterns of brain activity that may be associated with the condition. These parameters include: Alpha power, Beta power, Theta power, Delta power, Coherence, and more.

  38. Change in the TMS-EEG data [Baseline]

    Transcranial magnetic stimulation induces changes in cortical plasticity that can persist long after the end of stimulation. EEG is the sum of excitatory and inhibitory postsynaptic potentials, reflecting the rhythmic activity of neurons in the cerebral cortex.The stimulus response characteristics of TMS-EEG can be used to measure the cortical effects induced by TMS, to explore the functions of various brain regions, to correlate the causal relationship of inter-brain interactions, as well as to diagnose and treat depression based on abnormal response characteristics.

  39. Change in the TMS-EEG data [1 week]

    Transcranial magnetic stimulation induces changes in cortical plasticity that can persist long after the end of stimulation. EEG is the sum of excitatory and inhibitory postsynaptic potentials, reflecting the rhythmic activity of neurons in the cerebral cortex.The stimulus response characteristics of TMS-EEG can be used to measure the cortical effects induced by TMS, to explore the functions of various brain regions, to correlate the causal relationship of inter-brain interactions, as well as to diagnose and treat depression based on abnormal response characteristics.

  40. Change in the TMS-EEG data [2 weeks]

    Transcranial magnetic stimulation induces changes in cortical plasticity that can persist long after the end of stimulation. EEG is the sum of excitatory and inhibitory postsynaptic potentials, reflecting the rhythmic activity of neurons in the cerebral cortex.The stimulus response characteristics of TMS-EEG can be used to measure the cortical effects induced by TMS, to explore the functions of various brain regions, to correlate the causal relationship of inter-brain interactions, as well as to diagnose and treat depression based on abnormal response characteristics.

  41. Change of blood factor levels [Baseline]

    Factors carried by peripheral blood and exosomes(Hypocretin, Brain-derived neurotrophic fact, Reelin, N-methyl-D-aspartic acid receptor and so on).

  42. Change of blood factor levels [1 week]

    Factors carried by peripheral blood and exosomes(Hypocretin, Brain-derived neurotrophic fact, Reelin, N-methyl-D-aspartic acid receptor and so on).

  43. Change of blood factor levels [2 weeks]

    Factors carried by peripheral blood and exosomes(Hypocretin, Brain-derived neurotrophic fact, Reelin, N-methyl-D-aspartic acid receptor and so on).

  44. Change of blood factor levels [6 weeks]

    Factors carried by peripheral blood and exosomes(Hypocretin, Brain-derived neurotrophic fact, Reelin, N-methyl-D-aspartic acid receptor and so on).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Receive two or more adequate doses and courses of antidepressant drugs in different mechanisms that were not effective and had been stable for more than 6 weeks on antidepressant medication prior to enrollment, with non-responsiveness defined as a decrease in HAMD-24 score of <50%.

  2. 24-item Hamilton Depression Scale (HAMD-24) ≥ 20.

  3. Normal or corrected to normal vision.

  4. Ability to complete spatial suppression psychophysical experiment.

  5. education background above the college degree.

  6. Age 18-45 years, regardless of gender.

  7. Right-handedness.

  8. Han Chinese.

  9. Signed a written informed consent, willing to participate in the study and be evaluated.

Exclusion Criteria:
  1. Co-morbid other mental disorders, including: schizophrenia, mental retardation, substance dependence, etc.

  2. Patients with metal objects in the body or with other contraindications to PET-MRI scanning

  3. Patients with severe or unstable somatic diseases

  4. Women during pregnancy or lactation, and women of childbearing age with positive urine HCG test results during the screening period

  5. Benzodiazepines were taken during the experimental period

  6. Other conditions that, in the opinion of the investigator, exist that make participation in this clinical trial inappropriate.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang China 310000

Sponsors and Collaborators

  • First Affiliated Hospital of Zhejiang University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
First Affiliated Hospital of Zhejiang University
ClinicalTrials.gov Identifier:
NCT06044324
Other Study ID Numbers:
  • IIT20230029C-R1
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by First Affiliated Hospital of Zhejiang University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023